Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intergroup trial of rituximab added to chemotherapy in children and adolescents with high-risk B-cell NHL or B-ALL
NL-OMON55528Phase 3Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL) and primary mediastinal large B-cell lymphoma (PMBCL) (4 arms), sponsored by Gustave Roussy. Primary endpoint: Event-free survival. Started Jul 2014; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON55528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55528.